What is the long-term trend for GoodRx Holdings, Inc.'s cash and cash equivalents, end of period?

Over 4 years (2021 to 2025), GoodRx Holdings, Inc.'s cash and cash equivalents, end of period has grown at a -27.4% compound annual growth rate (CAGR), from $941.11M to $261.82M.

GoodRx Holdings, Inc. GDRX Cash and cash equivalents, end of period

Cash and cash equivalents, end of period at other companies

Phillips 66PSX

$5.15B+246%

3MMMM

$3.73B-41.1%

eBayEBAY

$4.23B+1.9%

American Financial GroupAFG

$1.35B+6.0%

Erie Indemnity CompanyERIE

$268.62M+3.2%

W.R. BerkleyWRB

$2.28B+32.6%

Other financials

Income statement

See full

Revenue$194.0M-4.4%

Gross profit$173.9M-8.3%

Operating income$14.0M-40.1%

Net income$1.2M-89.4%

EPS (diluted)$0.00-100%

Balance sheet

See full

Cash & equivalents$235.7M-21.7%

Total debt$541.4M0.0%

Total equity$622.0M-4.9%

Total assets$2.0B+56.0%

Cash flow

See full

Operating cash flow$11.8M+25.8%

CapEx$1.1M+700%

Free cash flow$10.7M+15.4%

Valuation

See full

Market cap$911.04M-44.5%

Enterprise value$1.22B-35.4%

P/E44.3×-13.4×

P/S1.2×-0.9×

Profitability

See full

Gross margin91.8%-2.0pp

Operating margin9.9%-0.3pp

Net margin2.6%-1.0pp

FCF margin21%+2.3pp

Returns & leverage

See full

Return on equity3.2%-1.2pp

Debt / equity0.9×0.0×

Current ratio1.5×-3.8×

Where this comes from

Reported directly by GoodRx Holdings, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations.

The official record: GoodRx Holdings, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about GoodRx Holdings, Inc.'s cash and cash equivalents, end of period.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is GoodRx Holdings, Inc.'s cash and cash equivalents, end of period?: GoodRx Holdings, Inc. (GDRX) reported cash and cash equivalents, end of period of $235.71M in Q1 2026.
How has GoodRx Holdings, Inc.'s cash and cash equivalents, end of period changed year-over-year?: GoodRx Holdings, Inc.'s cash and cash equivalents, end of period decreased by 21.7% year-over-year, from $300.98M to $235.71M.
What is the long-term trend for GoodRx Holdings, Inc.'s cash and cash equivalents, end of period?: Over 4 years (2021 to 2025), GoodRx Holdings, Inc.'s cash and cash equivalents, end of period has grown at a -27.4% compound annual growth rate (CAGR), from $941.11M to $261.82M.